COLLABORATIVE RESEARCH AGREEMENTCollaborative Research Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at 103 – 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3 (“UBC”)
EXECUTIVE EMPLOYMENT AGREEMENTEmployment Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
ASEP MEDICAL HOLDINGS INC., a British Columbia company, having its principal office located at 420 – 730 View Street, Victoria, British Columbia, V8W 3Y7
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Amalgamation Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and ABT INNOVATIONS INC. SchedulesLicense Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 123
SHARE PURCHASE OPTION AGREEMENTShare Purchase Option Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THIS AGREEMENT made as of the 14th day of May, 2021 (the “Effective Date”) between THE UNIVERSITY OF BRITISH COLUMBIA (“UBC”), ABT INNOVATIONS INC. (the “Company”) and ASEP MEDICAL INC. (the “Optionee”).
START-UP LICENSE AGREEMENT Between: THE UNIVERSITY OF BRITISH COLUMBIA and SAFECOAT MEDICAL INCLicense Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at #103-6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
OPTION AGREEMENTOption Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THIS AGREEMENT is dated as of May 14, 2021 (the “Effective Date”) among ASEP Medical Inc. (the “Optionee”), ABT Innovations Inc. (the “Optionor”) and each of the securityholders of the Optionor listed in Schedule “A” hereto (except UBC) (collectively, the “Securityholders” and individually each a “Securityholder”). The Optionor, the Optionee and each Securityholder are referred to herein as a “Party”, and together as the “Parties”.
ContractEmployment Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as private or confidential.
EARN-IN AND OPTION AGREEMENTIn and Option Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
FOR VALUABLE CONSIDERATION, the receipt and sufficiency of which is hereby acknowledged by the undersigned, the undersigned hereby:
LICENSE AGREEMENTLicense Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
SEPSET BIOSCIENCES INC., a corporation incorporated under the laws of British Columbia, with a registered and records office at Suite 700 - 401 West Georgia Street, Vancouver, BC Canada V68 5A1
ESCROW AGREEMENTEscrow Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances
THIS AGREEMENT is being entered into by the Parties under National Policy 46-201 Escrow for Initial Public Offerings (the “Policy”) in connection with the proposed non-offering prospectus by the Issuer, an emerging issuer.
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Feasibility Study Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
ABT INNOVATIONS INC., a company incorporated under the British Columbia Corporations Act and having its administrative offices at 200-931 Fort Street, Victoria, B.C. VBV 3K3 (“ABT”), Attention: Dr. Robert E. W. Hancock (“Provider Scientist”), Telephone: __________, E-mail: __________
EMPLOYMENT AGREEMENT THIS AGREEMENT is made on the 1st day of June 2021. BETWEENEmployment Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
WHEREAS the Employer desires to obtain the benefit of the services of the Employee, and the employee desires to render such services on the terms and conditions set forth;
JOINT VENTURE AND LICENSE AGREEMENTJoint Venture and License Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
NOW THEREFORE, in consideration of the mutual covenants in this Agreement and other good and valuable consideration, the receipt and sufficiency of all of which are hereby acknowledged by each Party, the Parties covenant and agree as follows:
ContractConsulting Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as private or confidential.
FIRST AMENDMENT TO CONFIDENTIAL DISCLOSURE AGREEMENT DATED 22 SEPTEMBER 2016Confidential Disclosure Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances
This First Amendment (the “Amendment”) to the Confidential Disclosure Agreement, dated 22 September 2016 (the “Agreement”), between ABT Innovations (“COMPANY”) and iFyber LLC (“IFYBER”), is entered into as of 18 May 2021.
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Consulting Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
WHEREAS the Company desires to obtain the benefit of the services of the Consultant, and the Consultant desires to render such services on the terms and conditions set forth;
COLLABORATIVE RESEARCH AGREEMENTAsep Medical Holdings Inc. • October 4th, 2024 • In vitro & in vivo diagnostic substances • British Columbia
THE UNIVERSITY OF BRITISH COLUMBIA, a corporation continued under the University Act of British Columbia with offices at 103 - 6190 Agronomy Road, Vancouver, British Columbia, V6T 1Z3
Pursuant to Item 601(b)(10)(iv) of Regulation S-K promulgated by the U.S. Securities and Exchange Commission, certain portions of this exhibit have been omitted because it is both not material and the type of information that the company treats as...Asep Medical Holdings Inc. • October 4th, 2024 • In vitro & in vivo diagnostic substances
Re: Collaborative Research Agreement between The University of British Columbia (“UBC”) and ABT Innovations Inc. (the “Sponsor”) effective as of June 2, 2021 (the “Agreement”); Amendment No. 1
OPTION AGREEMENTOption Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
THIS AGREEMENT is dated as of May 14 , 2021 (the “Effective Date”) among ASEP Medical Inc. (the “Optionee”), Sepset Biosciences Inc. (the “Optionor”) and each of the securityholders of the Optionor listed in Schedule “A” hereto (collectively, the “Securityholders” and individually each a “Securityholder”) including without limitation CDRD Ventures Inc. (the “Creditor”). The Optionor, the Optionee and each Securityholder are referred to herein as a “Party”, and together as the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
WHEREAS the Company desires to obtain the benefit of the services of the Consultant, and the Consultant desires to render such services on the terms and conditions set forth;
EMPLOYEE EMPLOYMENT AGREEMENTEmployment Agreement • October 4th, 2024 • Asep Medical Holdings Inc. • In vitro & in vivo diagnostic substances • British Columbia
ASEP MEDICAL HOLDINGS INC., a British Columbia company, having its principal office located at 420 – 730 View Street, Victoria, British Columbia, V8W 3Y7
